Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
|Articles|September 14, 2012
What to Look for at This Year’s ASCO Breast Cancer Symposium
Author(s)Tari A. King, MD
In this video, Tari A. King, MD, of the Memorial Sloan-Kettering Cancer Center, discusses what to look for at this year’s ASCO Breast Cancer Symposium.
Advertisement
In this video, Tari A. King, MD, of the Memorial Sloan-Kettering Cancer Center, discusses what to look for at this year’s ASCO Breast Cancer Symposium.
Advertisement
Related to this article
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5